Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Tsunoda

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Frontiers in Immunology|December 29, 2025
Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire studyHirotsugu Ariizumi, Miyuki Shimazui, Chisato Ogawa, et al.
Oncoimmunology|July 30, 2016
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLsMasatoshi Hirayama, Yusuke Tomita, Akira Yuno, et al.
Oncoimmunology|October 24, 2014
Identification of immunogenic LY6K long peptide encompassing both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell epitopes and eliciting CD4<sup>+</sup> T-cell immunity in patients with malignant diseaseYusuke Tomita, Akira Yuno, Hirotake Tsukamoto, et al.
Frontiers in Oncology|October 28, 2024
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patientsYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
Anticancer Research|July 26, 2024
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to TreatmentYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
Biomedicines|December 30, 2025
Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective StudyRisako Suzuki, Ryotaro Ohkuma, Makoto Watanabe, et al.
Frontiers in Oncology|July 29, 2025
Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancersMakoto Watanabe, Katsuaki Ieguchi, Nobuyuki Onishi, et al.
Cancers|July 29, 2025
Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot StudyMakoto Watanabe, Katsuaki Ieguchi, Takashi Shimizu, et al.
In Vivo (Athens, Greece)|April 29, 2021
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric CancerYutaro Kubota, Kiyoshi Yoshimura, Kazuyuki Hamada, et al.
Anticancer Research|October 1, 2021
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 ImmunotherapyKazuyuki Hamada, Kiyoshi Yoshimura, Yuya Hirasawa, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Frontiers in Immunology|December 29, 2025
Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire studyHirotsugu Ariizumi, Miyuki Shimazui, Chisato Ogawa, et al.
Oncoimmunology|July 30, 2016
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLsMasatoshi Hirayama, Yusuke Tomita, Akira Yuno, et al.
Oncoimmunology|October 24, 2014
Identification of immunogenic LY6K long peptide encompassing both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell epitopes and eliciting CD4<sup>+</sup> T-cell immunity in patients with malignant diseaseYusuke Tomita, Akira Yuno, Hirotake Tsukamoto, et al.
Frontiers in Oncology|October 28, 2024
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patientsYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
Anticancer Research|July 26, 2024
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to TreatmentYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
Biomedicines|December 30, 2025
Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective StudyRisako Suzuki, Ryotaro Ohkuma, Makoto Watanabe, et al.
Frontiers in Oncology|July 29, 2025
Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancersMakoto Watanabe, Katsuaki Ieguchi, Nobuyuki Onishi, et al.
Cancers|July 29, 2025
Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot StudyMakoto Watanabe, Katsuaki Ieguchi, Takashi Shimizu, et al.
In Vivo (Athens, Greece)|April 29, 2021
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric CancerYutaro Kubota, Kiyoshi Yoshimura, Kazuyuki Hamada, et al.
Anticancer Research|October 1, 2021
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 ImmunotherapyKazuyuki Hamada, Kiyoshi Yoshimura, Yuya Hirasawa, et al.
Pageof 13